Article ID Journal Published Year Pages File Type
9872008 International Journal of Radiation Oncology*Biology*Physics 2005 6 Pages PDF
Abstract
Conclusions: Amifostine administration during head-and-neck RT reduces the severity and duration of xerostomia 2 years after treatment and does not seem to compromise locoregional control rates, progression-free survival, or overall survival.
Keywords
Related Topics
Physical Sciences and Engineering Physics and Astronomy Radiation
Preview
Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head-and- neck cancer: 2-year follow-up of a prospective, randomized, phase III trial
Authors
, , , , , , ,